ヤロウ・バイオサイエンス
YARW
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.43 | $0 | -$90M |
| 2026 Q2 | -3.50 | $97,000 | -$2M |
| 2026 Q1 | -4.19 | $86,000 | -$4M |
| 2025 Q4 | -7.26 | $130,000 | -$4M |
| 2025 Q3 | -8.50 | $169,000 | -$7M |
| 2025 Q2 | -6.73 | $69,000 | -$11M |
| 2025 Q1 |
| -10.09 |
| $202,000 |
| -$11M |
| 2024 Q4 | -14.11 | $84,000 | -$9M |